HCL Technologies Launches a Global Hackathon to Identify Long-Term Technology Solutions to the COVID-19 Pandemic
20.8.2020 15:00:00 EEST | Business Wire | Press release
HCL Technologies , (HCL), a leading global technology company, today announced a multi-phase hackathon, “Better Health Hackathon: #CodeforCOVID19,” to crowdsource technology innovation to find solutions for the immediate and long-term societal impact of the COVID-19 pandemic, including pandemic containment and prevention; diagnosis, treatment and therapeutic management; recovery and return to normal; and systemic solutions for future crises.
As part of the program, HCL has partnered with Microsoft and International SOS, the world's largest medical and travel security services firm, who are providing business and technical oversight to the contest and feedback to team entries. In addition, the Better Health Hackathon is bringing together a wide-ranging and prestigious group of executives and companies, across multiple industries, to serve as judges and advisory panel members. This includes scholars from Johns Hopkins University, University of Cambridge, Tuck School of Business, The University of Queensland, Indian Institute of Technology, Kanpur, and subject matter experts from HCL.
The competition is open to technology innovators, entrepreneurs and problem solvers from the global developer community. To date the Better Health Hackathon has received more than 7500 registrations from 600+ unique organizations and academic institutions spanning 350 locations across 52 countries. To engage top talent in the coding community, the Hackathon is partnering with BeMyApp to leverage their expansive network of coders and tech enthusiasts. The Hackathon is open to eligible participants who are at least 18 years of age.
“The unique capabilities and strength of HCL’s global ecosystem of partners, coupled with the immense talent and best minds from the tech, developer and entrepreneur communities, enables us to make a significant contribution during the COVID-19 pandemic,” said Arthur Filip, Executive Vice President, Sales Transformation & Marketing, HCL Technologies. “Technology has a big role to play in alleviating the challenges brought on by the pandemic, addressing solutions for successful containment and the reorientation of business and society. We are honored to curate a very enthusiastic, committed and deeply talented global community to help us in this important work.”
Neeraj Balani, Managing Director, International SOS, India, said, “We are honored to be part of this initiative with our customer, HCL Technologies, and are confident that the outcomes will provide breakthroughs and benefits for employee health and wellness, which ultimately has a large impact on empowering business resilience, continuity and sustainability.”
Takuya Hirano, VP, Partner Services, Microsoft Corp., said, “This hackathon presents an opportunity for technology experts and innovative thinkers to showcase how advanced technology can help identify solutions to challenging problems facing societies. Technology can serve as a vehicle to drive new solutions that help improve the wellbeing of our communities and prepare us for future health challenges.”
Specifically, the HCL Better Health Hackathon: #CodeforCOVID19 will address the following areas:
-
Prevention and containment: #StayAtHome
- This track explores solutions that better safeguard the most vulnerable in our communities, better communicate credible information, and help people better cope with the challenges of self-isolation. This track will examine: How can technology aid efforts to #FlattenTheCurve by offering a better quality of life to encourage people to #StayAtHome.
-
Diagnosis, treatment & therapeutic management
- This track focuses on ways to help better protect and equip frontline healthcare workers and first responders, and to better serve those individuals and organizations seeking treatments and cures for COVID-19 with technology solutions.
-
Recovery and return to normal
- This track dives into the next phase of society after shutdown orders are removed. In the absence of a tested and available vaccine or therapeutic treatments against COVID-19, how can technology safeguard communities against a relapse of an outbreak, once social distancing and other restrictions are lifted throughout the world, allowing people to return to public spaces.
-
Systemic solutions for crises and pandemic management
- This track ideates innovative uses for next-gen technologies to plan for the long-term implications of COVID-19 and better prepare for future global pandemic-related challenges across healthcare and public services ecosystems.
About HCL Technologies
HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL’s Mode 1-2-3 strategy through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses transform into next-gen enterprises.
HCL offers its services and products through three business units - IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences & Healthcare and Public Services.
As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability and education initiatives. As of 12 months ended June 30, 2020, HCL has a consolidated revenue of US $ 9.93 billion and its 150,287 ideapreneurs operate out of 49 countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005438/en/
Contact information
For further details, please contact:
HCL Technologies
Anne Coyle, US
Anne.coyle@hcl.com
Elka Ghudial, Europe
Elka.ghudial@hcl.com
Devneeta Pahuja, India and APAC
Devneeta.p@hcl.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
